Current opinions on the role of pathogen reduction technology in improving the viral safety of blood and derivatives

被引：0
|
作者：
Seghatchian, Jerard [1 ]
机构：
[1] Blood Components Apheresis Technol & Haemostasis, London NW3 3AA, England
来源：
TRANSFUSION AND APHERESIS SCIENCE | 2008年 / 39卷 / 01期
关键词：
D O I：
10.1016/j.transci.2008.05.008
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：49 / 50
页数：2
相关论文
共 50 条
  • [41] Pathogen reduction and blood transfusion safety in Africa: strengths, limitations and challenges of implementation in low-resource settings
    Ware, A. D.
    Jacquot, C.
    Tobian, A. A. R.
    Gehrie, E. A.
    Ness, P. M.
    Bloch, E. M.
    [J]. VOX SANGUINIS, 2018, 113 (01) : 3 - 12
  • [42] THERAFLEX ultraviolet C (UVC)-based pathogen reduction technology for bacterial inactivation in blood components: advantages and limitations
    Schulze, Torsten J.
    Gravemann, Ute
    Seltsam, Axel
    [J]. ANNALS OF BLOOD, 2022, 7
  • [43] The effectiveness of riboflavin and ultraviolet light pathogen reduction technology in eliminating Trypanosoma cruzi from leukoreduced whole blood
    Jimenez-Marco, Teresa
    Cancino-Faure, Beatriz
    Girona-Llobera, Enrique
    Magdalena Alcover, M.
    Riera, Cristina
    Fisa, Roser
    [J]. TRANSFUSION, 2017, 57 (06) : 1440 - 1447
  • [44] Mirasol pathogen reduction technology treatment of human whole blood does not induce acute lung injury in mice
    Mallavia, Benat
    Kwaan, Nicholas
    Marschner, Susanne
    Yonemura, Susan
    Looney, Mark R.
    [J]. PLOS ONE, 2017, 12 (06):
  • [45] Replacement of Vector-Borne Disease Deferrals By Robust Pathogen Reduction Technology (PRT): A Study Based on Pathogen Loads in Blood Donors and Inactivation Efficacy
    Stramer, Susan L.
    Lanteri, Marion
    Spencer, Bryan R.
    Tonnetti, Laura
    Groves, Jamel
    Townsend, Rebecca
    Notari, Ed P.
    [J]. TRANSFUSION, 2020, 60 : 66A - 66A
  • [46] What is the role of technology in improving patient safety? A French, German and UK healthcare professional perspective
    Astier, Alain
    Carlet, Jean
    Hoppe-Tichy, Torsten
    Jacklin, Ann
    Jeanes, Annette
    McManus, Steve
    Pletz, Mathias W.
    Seifert, Harald
    Fitzpatrick, Ray
    [J]. JOURNAL OF PATIENT SAFETY AND RISK MANAGEMENT, 2020, 25 (06): : 219 - 224
  • [47] Assessment of Safety in Neonatal Rats for Transfusion of Red Blood Cells Prepared with the Amustaline-Gsh Pathogen Reduction Treatment
    von Goetz, M.
    North, A.
    Mufti, Nina
    Corash, L.
    [J]. TRANSFUSION, 2018, 58 : 65A - 65A
  • [48] Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation
    Fast, Loren D.
    DiLeone, Gilbert
    Marschner, Susanne
    [J]. TRANSFUSION, 2011, 51 (07) : 1397 - 1404
  • [49] Implementing pathogen reduction technology while discontinuing blood donor deferral criteria for sexual risk behaviors: A simulation study
    Domingue, Marie-Pier
    O'Brien, Sheila F.
    Gregoire, Yves
    Lanteri, Marion C.
    Stramer, Susan L.
    Lemyre, Felix Camirand
    Lewin, Antoine
    [J]. TRANSFUSION, 2024,
  • [50] Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026)
    Atreya, Chintamani
    Glynn, Simone
    Busch, Michael
    Kleinman, Steve
    Snyder, Edward
    Rutter, Sara
    AuBuchon, James
    Flegel, Willy
    Reeve, David
    Devine, Dana
    Cohn, Claudia
    Custer, Brian
    Goodrich, Raymond
    Benjamin, Richard J.
    Razatos, Anna
    Cancelas, Jose
    Wagner, Stephen
    Maclean, Michelle
    Gelderman, Monique
    Cap, Andrew
    Ness, Paul
    [J]. TRANSFUSION, 2019, 59 (09) : 3002 - 3025
12345